logo
Ontario deficit grows $10B as province tables $232.5B budget aimed at protecting economy from tariffs

Ontario deficit grows $10B as province tables $232.5B budget aimed at protecting economy from tariffs

CTV News15-05-2025

Ontario's deficit is expected to balloon by another $10 billion in 2025-26 as the Ford government spends billions of dollars on programs to support workers and stimulate the economy in the face of U.S. tariff threats.
'Ontario and all of Canada are at a precipice, and we need to take serious steps to make sure we do not find ourselves anywhere near the bottom,' Finance Minister Peter Bethlenfalvy said Thursday as he presented Ontario's latest budget, the first since the Ford government won re-election in March.
The government says it is setting aside $5 billion for the Protecting Ontario Account – a fund promised during the campaign to provide support to businesses facing 'significant tariff-related business disruptions.'
The province will also bolster the Skills Development Fund by another $1 billion over the next three years. There's also $500 million for a new Critical Minerals Fund the government says will 'unleash the potential' of the mineral sector.
Finance Minister Peter Bethlenfalvy called the tariffs imposed by the United States 'a wake-up call for Canadians' in prepared remarks but said this is a time for growth rather than fear.
The government says it plans to spend about $200 billion over the next 10 years on infrastructure. That will include $33 billion in 2025-26.
Over the next decade., the plan includes $30 billion for highway construction and rehabilitation; $61 billion for public transit, such as the GO 2.0 expansion and subway projects; $56 billion for health care infrastructure; and around $30 billion to build more schools and child care spaces.
Many of the measures included in the budget were previously unveiled.
As announced earlier this week by Premier Doug Ford, the budget keeps an election promise to permanently lower the gas tax and to eliminate tolls on a provisionally owned portion of Hwy. 407 East, between Clarington and Pickering.
Last week Bethlenfalvy announced an expansion of the Ontario Made Manufacturing Investment Tax Credit – a tax credit meant to bolster Ontario's manufacturing sector. That will provide $1.3 billion over three years to help the sector.
A six-month deferral of some taxes for businesses, worth $9 billion, was announced in April and is also included in the budget.
Impact of tariffs still uncertain
The new spending means the government is now projecting a deficit of $14.6 billion in 2025-26 -- $10 billion more than last year's budget predicted and $13 billion more than the fall economic statement projected just a few months ago.
A deficit of $7.8 billion is expected in 2026-27 instead of the $500 million surplus that had been projected previously.
The government still believes that it can balance the books by 2027-28, predicting a small surplus of $200 million in that fiscal year.
Fiscal outlook
Ontario's 2024-25 deficit is now projected to be $6 billion -- $3.8 billion lower than the 2024 budget predicted. The government says that's due to higher-than-expected tax revenue.
While there have been fears that tariffs could send Ontario's economy into a recession, the budget actually predicts mild growth.
Ontario's real GDP grew by 1.5 per cent in 2024, but is expected to rise by just 0.8 per cent in 2025 and one per cent in 2026 because of tariffs. GDP is forecast to grow by 1.9 per cent in 2027-28.
However, ministry staff stress that the economic environment remains highly unpredictable. They say that the impact of tariff actions has not yet been fully observed in recent economic data, but forward-looking economic indicators are down significantly, close to levels not seen since the pandemic.
No major increases for health, education spending
The government plans to spend $91.1 billion on health care. That's up from $89.3 billion from last year, but the increase is still less than inflation.
While health care spending growth looks somewhat flat, the government says that's because of higher costs in previous years when the province experienced an influx of newcomers and there were added pressures on OHIP.
Spending in 2025-26 will include $235 million to create and expand 305 additional primary care teams as part of a plan announced in January to connect more Ontarians with primary care.
The latest budget also includes a fertility tax credit that would cover 25 per cent of fertility treatments up to $20,000 per year, for a maximum of $5,000.
Education spending is up at $1 billion, compared to $38. 4 billion last year, but it appears that it will remain relatively flat for the next two years. The government says that's because of higher capital spending in previous years.
Wher your money goes
Opposition slams budget as 'band-aid'
Opposition Leader Marit Stiles slammed the government's latest budget at Queen's Park Thursday, calling it a missed opportunity to strengthen the province.
'This is a band-aid budget, a missed opportunity to strengthen Ontario,' Stiles said.
She said she was 'shocked' there was plenty of discussion around alcohol prices, but little attention to child care or post-secondary spending.
When it comes to housing, MPP Jessica Bell said the government 'quite frankly have thrown in the towel on housing in this budget.'
When it comes to housing, the government is lowering its projections, expecting just 71,800 housing starts for 2025. That's about 20,000 fewer housing starts than the 92,300 predicted in the 2024 budget. The forecast has also been lowered by about 20,000 homes for 2026 and about 13,000 homes for 2027.
However the government notes that those are macro-economic projections which may differ from the ministry's real-time numbers, which could potentially be higher.
Ontario has set a goal of building at least 1.5 million homes by 2031 and needs to build more than 100,000 homes each year to stay on track. Bethlenfalvy said Thursday they are still committed to that goal.
The budget includes no new details on Premier Doug Ford's proposal to build a vehicle and transit tunnel under Highway 401 to relieve gridlock, simply saying that feasibility work will be carried out.
Other highlights
$75.5M extra beyond annual funding to homelessness prevention programs, such as boosting shelter capacity and ready-to-build affordable housing projects
$57M on helicopters for police in Niagara and Windsor
$15.5M more over three years to increase production of medical isotopes to 24 hours a day
The province will create an 'Ontario Grown' badge this summer for cannabis products with at least 75 per cent Ontario content
Cannabis shop windows will no longer have to be blacked out to 'increase comfort, security, and safety' of customers and employees, though products cannot be visible from the outside
The province will be making various changes to alcohol pricing and taxes, with revenue from the LCBO and the beer, wine and spirits tax expected to drop significantly in 2025-26.
-With files from CTV Toronto's Siobhan Morris

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?

Globe and Mail

time26 minutes ago

  • Globe and Mail

Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Disrupting the healthcare market Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk 's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Going abroad and personalization Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. HIMS Gross Profit Margin data by YCharts. Should you buy Hims & Hers stock? A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025

Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia
Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia

Globe and Mail

timean hour ago

  • Globe and Mail

Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia

There will prove to be many winners as artificial intelligence (AI) infrastructure continues to grow and AI end-uses expand. Nvidia (NASDAQ: NVDA) has been the Wall Street darling surrounding everything AI for the past two years. CoreWeave (NASDAQ: CRWV) has been getting the love most recently, though. Shares of the AI hyperscaler providing cloud services have soared about 185% in just the past month as of this writing. Nvidia stock has increased 24% in that time. CoreWeave just went public in late March, and the shares have jumped about 270% since that initial public offering (IPO). Investors may wonder if Nvidia's shine is fading, and it's time to buy CoreWeave instead. I'd argue that is flawed thinking, however. The growth isn't over for Nvidia Investors may be taking a breather after the early exponential gains in Nvidia stock. Growth in the business itself has also slowed, though that was inevitable. Sales of its advanced chips in the data center segment had been growing like a weed. Revenue in that segment has been increasing in each consecutive quarter for the last two years. In the most recent fiscal quarter, that growth rate slowed to 10%, though, as seen below. Despite that trend, it's clear AI demand hasn't yet peaked. Remember, these are still sequential quarterly increases in data center sales. For perspective, that fiscal first-quarter revenue was a 73% jump compared to the prior year period. Management also guided investors to expect further revenue growth in the current quarter. So, while an unsustainable growth rate slows, the company is still solidly in growth mode. Nvidia is more ubiquitous than you might think That's because it's not just Nvidia's advanced GPU and CPU chips driving sales and expanding AI infrastructure. Its AI ecosystem includes interconnect technologies, the CUDA (compute unified device architecture) software platform, and artificial intelligence processors that are part of many different types of architectures. CEO Jensen Huang recently touted Nintendo 's new Switch 2 gaming console, for example. The unit includes Nvidia's AI processors that Huang claims "sharpen, animate, and enhance gameplay in real time." Nvidia has a broad array of customers. As AI factories and data centers are built, it will continue to be a major supplier and one that investors should benefit from owning. Nvidia also invests in the AI sector. It makes sense to look at where the AI leader itself sees future gains. Nvidia thinks CoreWeave is a good investment One of the AI companies in which Nvidia holds a stake is CoreWeave. Nvidia should know CoreWeave well, too, as an important customer. CoreWeave leases data center space to companies needing the scalable, on-demand compute power it has control of from the 250,000 Nvidia chips it has purchased. It's a desirable option for enterprises that require significant computational power to process large amounts of data efficiently. There appears to be plenty of demand. But there is plenty of risk for investors, too. It just announced a new lease agreement to further increase capacity. Applied Digital, a builder and operator of purpose-built data centers, has agreed to deliver CoreWeave 250 megawatts (MW) of power load on a 15-year term lease at its recently built North Dakota data center campus. CoreWeave has the option to expand the load by an additional 150 MW in the future. Demand is quickly driving growth for CoreWeave. That's led investors to jump in and drive the stock higher in recent months. Valuation is just one major risk with CoreWeave. Customer concentration is another. Last year, Microsoft accounted for nearly two-thirds of revenue. CoreWeave also disclosed that 77% of 2024 revenue came from just its top two customers. CoreWeave is also spending massive amounts of capital to grow AI cloud capacity. It had about $5.4 billion of liquidity available as of March 31 and raised another $2 billion from a late May debt offering. That's approximately its level of capital expenditure in just the first quarter alone, though. CoreWeave has the risk, Nvidia has the profits That spending may pay off. But there are risks there as well. Customers could develop their own AI infrastructure or could redesign systems that don't require its services. CoreWeave stock also trades at a high valuation after the stock has soared. It recently had a price-to-sales (P/S) ratio of about 30. That could be cut in half this year with its strong sales growth, but it isn't earning any money yet. At the same time, Nvidia sports a price-to- earnings (P/E) ratio of about 30 based on this year's expected profits. Remember, too, that as CoreWeave grows, so do Nvidia's profits. Applied Digital CEO Wes Cummins said that its leased North Dakota data center campus will be full of Nvidia Blackwell class servers. I think the risk profile, financial picture, and massive potential for Nvidia make it the better AI stock to buy now. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store